In May, Kinney Drugs gave its phone system a name. Patients calling the Vermont and New York pharmacy chain to refill a prescription no longer reached a touch-tone menu or a person — they reached "Burt," an AI voice assistant named after the chain's founder, built by a Texas company called Synerio. By early August, after hundreds of complaints reported by local outlet WCAX, Burt was being pulled off the phones. Incoming calls are going back to the old touch-tone system.

The reversal is worth sitting with, because Kinney Drugs did not retreat over an abstract fear of AI. It retreated because the thing did not work in the one place it was pointed — and the place it was pointed was people trying to get their medication.

What patients described

The complaints, collected by VTDigger in a late-July investigation, are not about tone or novelty. They are about the assistant failing at the task.

Kathy Callaghan, a customer, said of Burt: "He calls you all the time, and he doesn't say what the drug is," and that she ended up with "four bottles of something that I take twice a week sitting here." Maria Aveni described the assistant as effectively mandatory: "Burt demands that you talk to him. … So it's more of a talk to Burt or don't get your drugs." Others were blunter. "It has absolutely no value, no benefit to the customer," said Dave Bellini. "They got a winning team there, and they got great humans. They should have never gone to robots."

The reported failures were operational, not cosmetic: delays between a physician's order and the pharmacy processing it, an inability to locate customer accounts, incorrect dosages, missed pickup notifications, inaccurate drug listings, and refill messages landing in spam folders. In a pharmacy, each of those is not an inconvenience but a missed dose.

What the company kept, and what it dropped

Kinney Drugs president John Marraffa told WCAX that the technology had not gotten the customer experience "right," while defending its security. The company's fix is telling in its shape. Inbound phone calls revert to the touch-tone system. But Burt is not gone: it stays on for outbound refill texts — with one change. Those messages now require patients to opt in, where before they were automatic.

That split is the most instructive part of the whole episode. The company did not conclude "AI is bad." It concluded that an AI voice agent standing between a patient and their prescription — a high-stakes interaction with almost no tolerance for error, and no easy way for the patient to route around it — was the wrong place for the technology. A low-stakes, opt-in reminder text is a place it can survive. The dividing line the company drew, under pressure, is a line about where an unreliable system is allowed to fail.

The privacy layer

There is a second thread underneath the operational one. Kinney Drugs' own privacy policy discloses that customer data may be used in AI tools, and routing calls through Burt means routing protected health information through a third-party vendor. Joseph Near, an associate professor of computer science at the University of Vermont, noted that involving an outside company raises the privacy exposure rather than lowering it. The chain's terms, patients found, span eleven separate documents.

The regulatory backstop is not much of one. Vermont signed a data privacy bill in June 2026 — but it does not take effect until 2028. For the window in which a deployment like this actually happens, consumer protection is mostly the company's own judgment.

Why this one matters beyond Vermont

It would be easy to file this as a small-town story about a regional chain. It reads better as a clean, early example of a pattern that is going to repeat: a business deploys a customer-facing AI agent to cut cost and friction, discovers that the agent's error rate is fine in a demo and unacceptable in production, and walks it back after the customers — not a regulator, not a researcher — refuse it.

The lesson is not that voice AI cannot work. It is that the deployment decision is the whole game. The interactions where AI saves the most money are often the ones with the least room for it to be wrong, and a patient who cannot get a straight answer about their prescription has both the motive and, eventually, the leverage to reject it. Kinney Drugs learned where its line was by crossing it in public. The next company gets to read the map.